Results 161 to 170 of about 2,340 (175)

Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure

Cancer Cell, 2017
Benjamin Haley, Trinna L Cuellar, Jinfeng Liu   +2 more
exaly  

Ferroelectric memory for back-end-of-line 3D integration

Nature Reviews Materials, 2023
exaly  

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Lancet, The, 2012
Laura E Via, Clifton E Barry Iii, Cesar Bonilla   +2 more
exaly  

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Lancet, The, 2018
Matsatoshi Kudo, Kwang-Hyub Han, Fabio Piscaglia   +2 more
exaly  

Preserving Primary Care: the Front Line in the War Against Cancer

Ca-A Cancer Journal for Clinicians, 2007
exaly  

Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial

Lancet, The, 2019
Stuart R Dalziel, Meredith L Borland, Jeremy S Furyk   +2 more
exaly  

Anal cancer: Current standards in care and recent changes in practice

Ca-A Cancer Journal for Clinicians, 2015
exaly  

Uridylation by TUT4/7 Restricts Retrotransposition of Human LINE-1s

Cell, 2018
Zbigniew Warkocki, Pawel S Krawczyk, Andrzej Dziembowski   +2 more
exaly  

Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness

Ca-A Cancer Journal for Clinicians
exaly  

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Ca-A Cancer Journal for Clinicians
exaly